Today, advances in cross-sectional imaging have led to the detection and early recognition of incidental/focal liver lesions (FCL). In approximately 17,000 cases of chest CT, incidental liver lesions were found in 6% [1]. In general, FCL consists of hepatocytes, biliary epithelium, mesenchymal tissue, connective tissue, or metastasized cells from distant sites. Most incidental lesions are benign, some may require careful management and treatment. In evaluating the lesion, the patient’s clinical history, underlying disease and age factor should be considered. FCL can be detected at a rate of 10-30% in normal healthy and chronic liver disease patients, and even in oncology patients with malignancy, FCLs can be highly benign (50-80%).
Today, advances in cross-sectional imaging have led to the detection and early recognition of incidental/focal liver lesions (FCL). In approximately 17,000 cases of chest CT, incidental liver lesions were found in 6% [1]. In general, FCL consists of hepatocytes, biliary epithelium, mesenchymal tissue, connective tissue, or metastasized cells from distant sites. Most incidental lesions are benign, some may require careful management and treatment. In evaluating the lesion, the patient's clinical history, underlying disease and age factor should be considered. FCL can be detected at a rate of 10-30% in normal healthy and chronic liver disease patients, and even in oncology patients with malignancy, FCLs can be highly benign (50-80%)
Today, advances in cross-sectional imaging have led to the detection and early recognition of incidental/focal liver lesions (FCL). In approximately 17,000 cases of chest CT, incidental liver lesions were found in 6% [1]. In general, FCL consists of hepatocytes, biliary epithelium, mesenchymal tissue, connective tissue, or metastasized cells from distant sites. Most incidental lesions are benign, some may require careful management and treatment. In evaluating the lesion, the patient’s clinical history, underlying disease and age factor should be considered. FCL can be detected at a rate of 10-30% in normal healthy and chronic liver disease patients, and even in oncology patients with malignancy, FCLs can be highly benign (50-80%).
Esophageal granular cell tumors (GCTs) are rare, often benign tumors of neurogenic origin. Granular cell tumors (GCTs), first described by Abrikossoff in 1926, are rare tumors that occur in various parts of the body [1,2]. They are generally observed in the gastrointestinal tract, less commonly in the thyroid, respiratory tract, female urogenital tract, nervous system, breast, and gastrointestinal (GI) tract [1,2]. Tumors in the gastrointestinal tract represent only 6-10% of all granular cell tumors, especially the esophagus. In 30-60% of these cases, the most common location is the esophagus [1,3]. These neoplasms are usually solitary and are multifocal lesions in 10% of cases. Although their clinical course is relatively benign, approximately 2% of GCTs are malignant.
Prostate cancer is the most common cancer in men and has a high risk of metastasis. It often metastasizes to the iliac lymph nodes, bone, lungs, less frequently to the bladder, liver, and adrenals. The most common location for distant metastases is the bones. Although it is a frequently metastasizing cancer, rectal metastasis is rare. Few cases have been reported in the literature. In this case, we discuss the rectal invasion that occurred years later in a patient who presented with constipation and underwent prostate cancer surgery 15 years ago.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.